Back to search results

MANAGE-AF Registry for Atrial Fibrillation

This study, called MANAGE-AF, is an observational registry designed to learn more about the usual care for people with atrial fibrillation (AF), which is an irregular heartbeat. AF can increase your risk of stroke. Researchers want to understand how doctors treat AF, how treatments differ, and how these treatments help prevent strokes and manage symptoms. They will collect information on how AF progresses and how different treatments, like those that control heart rhythm or rate, are used over time. You may be able to join if you are 18 or older and have a diagnosis of AF. The study aims to enroll 1000 participants and will track outcomes like AF recurrence, blood clot events, and mortality for up to 10 years.

Study design
This is an observational study, meaning participants will receive their usual care, and researchers will collect information about it. The study plans to enroll 1000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment up to 10 years for outcomes like AF recurrence, blood clot events, and mortality.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05978466

MANAGE-AF Registry -MANAGEment of Atrial Fibrillation Outcomes Registry (MANAGE-AF)

Recruiting
Not specifiedAges 18+Observational
CorVita Science Foundation
~1,000 participants
Updated 2024-01-18 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recurrence of Atrial fibrillation
Measured over From enrollment to 10- year study completion
+2 more outcomes measured

Conditions

Atrial Fibrillation

Explore related trials

Atrial Fibrillation

NCT05978466

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • CorVita Science Foundation (NFP)

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Martin C Burke, DO · PRINCIPAL_INVESTIGATOR · Chief Scientific Officer

Who to contact

Edward M Burke
[email protected]
773-432-4888
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Recurrence of Atrial fibrillationFrom enrollment to 10- year study completion

    The natural progression of the condition will be assessed per medical record review

  • Number of participants who had thrombo-embolic eventFrom enrollment to 10- year study completion

    All strokes, transient ischemic and systemic thrombo-embolic events

  • MortalityFrom enrollment to 10- year study completion

    All cause death will be noted